The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary (2010)
Chapter: Appendix A: References
A
References
BVGH (BIO Ventures for Global Health). 2006. Advance market commitments to stimulate industry investment in global health product development. http://bvgh.org/LinkClick.aspx?fileticket=W_5VAgleR8k%3d&tabid=91 (accessed March 18, 2010).
Center for Arms Control and Non-Proliferation: Scientists working group on biological and chemical weapons. 2010. Biological Threats: A Matter of Balance. Statement released January 26, 2010. http://www.armscontrolcenter.org/policy/biochem/articles/biological_threats_a_matter_of_balance (accessed March 8, 2010).
FDA (Food and Drug Administration). 2004. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathIniative/CriticalPathOpportunitiesReports/UCM113411.pdf (accessed March 4, 2010).
FDA. 2007. FDA science and mission at risk. Report of the Subcommittee on Science and Technology. http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4329b_02_01_FDA%20Report%20on%20Science%20and%20Technology.pdf (accessed March 9, 2010).
Graham, B., and J. Talent. 2009. Bioterrorism: Redefining prevention. Biosecurity and Bioterrorism: Biodefense strategy, practice, and science. 7(2):125–126. http://www.liebertonline.com/doi/pdfplus/10.1089/bsp.2009.0610?cookieSet=1 (accessed March 15, 2010).
IOM (Institute of Medicine). 2008. The U.S. commitment to global health: Recommendations for the new Administration. Washington, DC: The National Academies Press.
IOM. 2009. Venture philanthropy strategies to support translational research: Workshop summary. Washington, DC: The National Academies Press.
IOM and NRC (National Research Council). 2004. Giving full measure to countermeasures: Addressing problems in the DoD program to develop medical countermeasures against biological warfare agents. Washington, DC: The National Academies Press.
LSE (The London School of Economics and Political Science). 2010. Policies and incentives for promoting innovation in antibiotic research. http://www2.lse.ac.uk/newsAndMedia/news/archives/2009/09/antibiotics.aspx (accessed March 14, 2010).
Matheny, J., M. Mair, and B. Smith. 2008. Cost/success projections for U.S. biodefense counter-measure development. Nature Biotechnology 26(9):981–983.
Melese, T., S. M. Lin, J. L. Chang, and N. H. Cohen. 2009. Open innovation networks between academia and industry: An imperative for breakthrough therapies. Nature Medicine 15:502–507.
NBSB (National Biodefense Science Board). 2010a. Where are the Countermeasures? Protecting America’s Health From CBRN Threats. http://www.hhs.gov/aspr/barda/documents/phemceimplplan_041607final.pdf (accessed May 17, 2010).
NBSB. 2010b. Optimizing industrial involvement in medical countermeasure development. http://www.hhs.gov/aspr/omsph/nbsb/nbsbrpt-2010.pdf (accessed March 2, 2010).
PhRMA. 2010. R&D investment by U.S. biopharmaceutical companies remains strong despite ongoing economic challenges. http://www.phrma.org/news/news/rd_investment_us_biopharmaceutical_companies_remains_strong_despite_ongoing_economic_chall (accessed March 30, 2010)
Wolf, M. C., A. N. Freiberg, T. Zhang, A. Akyol-Ataman, A. Grock, et al. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proceedings of the National Academy of Sciences 107(7):3157–3162.
